We can’t show the full text here under this license. Use the link below to read it at the source.
Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
Cotadutide's effects on metabolism and liver health in overweight adults with type 2 diabetes over 54 weeks
AI simplified
Abstract
Cotadutide significantly decreased glycated hemoglobin A (HbA1c) and body weight at weeks 14 and 54 compared to placebo (all < 0.001).
- Improvements in lipid profile, liver enzyme levels, and liver fibrosis assessments were noted with cotadutide 300 μg compared to placebo.
- Weight loss achieved with cotadutide 200 μg was comparable to liraglutide 1.8 mg, while cotadutide 300 μg resulted in greater weight loss than liraglutide.
- The most common adverse events associated with cotadutide were nausea (35%) and vomiting (17%), which decreased over time.
- Cotadutide treatment is associated with enhanced glycemic control and weight reduction in individuals with overweight/obesity and type 2 diabetes.
- Preliminary analyses suggest potential benefits of cotadutide for liver health, indicating a need for further investigation in nonalcoholic steatohepatitis (NASH).
AI simplified